Phase I Dose Escalating Study of TKI258

• Written informed consent must be obtained prior to any screening procedures
• Advanced solid tumors
• Agreement to remaining hospitalized
• ECOG performance status of 0 or 1
• Life expectancy of at least 3 months
• Pregnant women. Male and female patients of reproductive potential must agree to employ an effective method of birth control
• Demonstrate the specific hematological /blood chemistry laboratory values

Exclusion Criteria:

• Receipt of any investigational compound within 28 days prior to the first dose of study drug or failure to have recovered from the side effects of such prior therapy
• Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and radiation therapy, within 28 days (with some exceptions)
• Patients with CNS and/or leptomeningeal disease metastases
• Presence or history of thromboembolic or cerebrovascular events
• Impaired cardiac function or clinically significant cardiac disease
• Malabsorption syndrome or uncontrolled gastrointestinal toxicities
• Patients known to be HIV- or HBV- or HCV- positive
• Patients with acute or chronic uncontrolled infection
• Patients who have undergone surgery with general anesthesia for any cause within 28 days prior to the first dose of study drug
• Patients who have been receiving anticoagulant therapy
• Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14 days prior to the first dose of study drug
• Patients who have been administering concomitant medication which may prolong the QTc interval
• Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan
• Patients with a large volume of ascitic and/or pleural fluid which requires drainage
• Patients with any bone fractures
• Deemed otherwise unsuitable by the investigator

Other protocol-defined inclusion/exclusion criteria may apply